Peter Ordentlich - 29 Jul 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Scientific Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
29 Jul 2022
Net transactions value
-$464,086
Form type
4
Filing time
26 Aug 2022, 16:14:47 UTC
Previous filing
03 Feb 2022
Next filing
02 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Other $3,742 +265 $14.12 265 29 Jul 2022 Direct F1
transaction SNDX Common Stock Options Exercise $144,387 +22,846 +8621% $6.32 23,111 24 Aug 2022 Direct
transaction SNDX Common Stock Sale $571,966 -22,846 -99% $25.04 265 24 Aug 2022 Direct F2, F3
transaction SNDX Common Stock Options Exercise $13,678 +2,154 +813% $6.35 2,419 24 Aug 2022 Direct
transaction SNDX Common Stock Sale $53,927 -2,154 -89% $25.04 265 24 Aug 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -2,154 -100% $0.000000* 0 24 Aug 2022 Common Stock 2,154 $6.35 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -22,846 -100% $0.000000* 0 24 Aug 2022 Common Stock 22,846 $6.32 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 265 shares by the Reporting Person on 07/29/2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,647 options to purchase shares of common stock that are vested and immediately exercisable and a total of 148,194 options to purchase shares of common stock that have not yet vested.
F3 The sale prices ranged from $25.00 to $25.18.
F4 This option is fully vested.